Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
A clinical trial of once-weekly TZT in T2DM patients illustrated that at 26 weeks of treatment, TZT led to the significant reduction of intercellular adhesion molecule 1 (ICAM-1), growth differentiation factor 15 (GDF-15), chitosan-3 like protein 1 (YKL-40), leptin and CRP compared to the baseline values
Moreover, it effectively eliminates fat and shapes the body
Explore More at Pharmeasy Manufacturer Details Brand:OXONEG Manufacturer Name:IPCA LABORATORIES Address:Lyka Labs Ltd.,Plot No
Quality assessment The methodological quality of the included studies was evaluated using the Newcastle-Ottawa Scale (NOS) [24], which assesses three domains: selection of study participants, comparability between groups, and the ascertainment of exposure or outcomes, with a maximum achievable score of 9 points
US$ 24.52
US$ 22.93
US$ 29.45
